A clinical case of 3-year highly efficient pembrolizamable therapy of metasatic lung adenocarcinoma

Abstract

Immunotherapy presents a new promising approach to the treatment of disseminated lung cancer. Pemriblisumab (Kitruda®) is one of the antiPD-1 drugs registered in Russia, which is used in both the secondand, in the event of high-level PD-L1 expression (≥50%), the first-line therapy. This paper presents a clinical observation of a highly efficient pemribrolizumab treatment of a patient with metastatic adenocarcinoma.

Keywords

• pemribrolizumab
• non-small cell lung cancer
• pd-1
• pd-l1